Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study and are willing to sign an approved consent form
- People who are between 18 and 64 years old at the time of signing consent
- People who have been newly diagnosed with Acute Myeloid Leukemia (AML), a type of blood cancer, confirmed by a bone marrow biopsy
- People who are planned to receive intensive chemotherapy to treat their AML (it is acceptable if chemotherapy has already started, as long as it began within the last 30 days)
- People who are able to read and understand English and/or Spanish
- People who, in the opinion of the study doctor, are able to understand and follow the study procedures for the full duration of the study
Who may not be able to join:
- People who have been diagnosed with a specific subtype of blood cancer called Acute Promyelocytic Leukemia
- People who are unwilling to receive intensive chemotherapy for AML
- People who have previously received treatment for any blood cancer
- People who have previously had a stem cell transplant using donor cells (allogeneic hematopoietic stem cell transplant)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thomas Knight, MD, Wake Forest University Health Sciences
Phone: (980) 442-2327
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Self-reported financial toxicity as assessed by the total score of the COmprehensive Score Financial Toxicity (COST) assessment tool at 6 months after enrollment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.